StackTerminal.Health

Vitamin K2 (MK-7)

Menaquinone-7 (MK-7) is the long-chain form of vitamin K2 that activates matrix Gla-protein and osteocalcin, directing calcium to bone rather than arterial walls; evidence from RCTs demonstrates preservation of bone mineral density and reduction of vertebral height loss in postmenopausal women.

bonecardiovascularlongevitycalcium-metabolismhormonal
Dosing model
FLATFixed dose (no body-weight scaling).
Min dose
0 mg
Max dose
0 mg
Rounding
0 mg

Stacks containing Vitamin K2 (MK-7)

Public community stacks that include this ingredient.

Explore all stacks →
No public stacks include this ingredient yet.
Evidence
2 records
Bone mineral density and vertebral fracture prevention
Healthy postmenopausal womenRCT
Moderate

A 3-year double-blind RCT (n=244) of MK-7 180 mcg/day found significantly attenuated age-related decline in bone mineral content and BMD at lumbar spine and femoral neck versus placebo, plus reduced vertebral height loss in the lower thoracic region; bone strength indices were also favorably affected.

Dose: 0 mg Duration: 3 years
Dose expressed in mg (180 mcg = 0.18 mg). MK-7 has a ~72-hour half-life enabling once-daily dosing.
Fracture incidence and bone density in postmenopausal osteoporosis
Postmenopausal women with or at risk for osteoporosissystematic review and meta-analysis of RCTs
Moderate

Meta-analysis of 16 RCTs (n=6,425) found vitamin K2 supplementation significantly improved lumbar spine BMD and reduced fracture incidence after exclusion of one outlier study; undercarboxylated osteocalcin was consistently reduced, indicating enhanced bone mineralization.

Dose: 0 mg Duration: 6 months – 3 years
Forms